Disaster at Amarin: Stock plummets 70% after Vascepa patent challenge loss

30th March 2020 Uncategorised 0

Only months ago, hopes for Amarin, the maker of fish-oil derivative Vascepa, were sky high after the FDA expanded the drug’s label to include heart-helping language with blockbuster potential. But those hopes have come crashing down after a judge invalidated Vascepa’s underlying patents.

More: Disaster at Amarin: Stock plummets 70% after Vascepa patent challenge loss
Source: fierce